|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-1.92/-2.01
|
企业价值
568.62M
|
资产负债 |
每股账面净值
3.74
|
现金流量 |
现金流量率
--
|
损益表 |
收益
63.53M
|
每股收益
1.05
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/18 21:10 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients. |